Disease-modifying therapies for relapsing/active secondary progressive multiple sclerosis–a review of population-specific evidence from randomized clinical trials
A Bayas, M Christ, S Faissner… - Therapeutic …, 2023 - journals.sagepub.com
Although the understanding of secondary progressive multiple sclerosis (SPMS) is evolving,
early detection of relapse-independent progression remains difficult. This is further …
early detection of relapse-independent progression remains difficult. This is further …
Pharmacological approaches to the management of secondary progressive multiple sclerosis
A Nandoskar, J Raffel, AS Scalfari, T Friede… - Drugs, 2017 - Springer
It is well recognised that the majority of the impact of multiple sclerosis (MS), both personal
and societal, arises in the progressive phase where disability accumulates inexorably. As …
and societal, arises in the progressive phase where disability accumulates inexorably. As …
To stop or not to stop disease modifying therapies in secondary progressive multiple sclerosis, that is the question
E D'Amico, T Ziemssen, S Cottone - Expert Review of …, 2017 - Taylor & Francis
The predominant clinical disease course of multiple sclerosis (MS) which can be treated
today by a variety of different disease-modifying treatments (DMT) is characterized by …
today by a variety of different disease-modifying treatments (DMT) is characterized by …
New treatments and treatment goals for patients with relapsing-remitting multiple sclerosis
EJ Fox, RW Rhoades - Current opinion in neurology, 2012 - journals.lww.com
New MS treatments may provide the basis for aggressive early intervention in patients with
MS and intensification of treatment when disease is not controlled. The availability of …
MS and intensification of treatment when disease is not controlled. The availability of …
Therapeutic advances and challenges in the treatment of progressive multiple sclerosis
LE Baldassari, RJ Fox - Drugs, 2018 - Springer
Despite the fact that majority of patients with multiple sclerosis (MS) have relapsing-remitting
disease, many transition to secondary progressive disease (SPMS) over time. This transition …
disease, many transition to secondary progressive disease (SPMS) over time. This transition …
The changing face of multiple sclerosis clinical trial populations
BMJ Uitdehaag, F Barkhof, PK Coyle… - … medical research and …, 2011 - Taylor & Francis
Background: Since the commercial introduction of disease-modifying drugs (DMDs) for the
treatment of multiple sclerosis (MS), there have been numerous randomized placebo …
treatment of multiple sclerosis (MS), there have been numerous randomized placebo …
Established disease-modifying treatments in relapsing-remitting multiple sclerosis
J Oh, PW O'Connor - Current opinion in neurology, 2015 - journals.lww.com
The treatment algorithm for RRMS is becoming increasingly complex with the ever-
expanding armamentarium of DMTs. The choice of DMT will become an increasingly …
expanding armamentarium of DMTs. The choice of DMT will become an increasingly …
Can we treat secondary progressive multiple sclerosis now?
R Bhatia, N Singh - Annals of Indian Academy of Neurology, 2019 - journals.lww.com
Secondary progressive multiple sclerosis (SPMS) is characterized by progressive
accumulation of disability without intermittent recovery. Treatment of these patients is …
accumulation of disability without intermittent recovery. Treatment of these patients is …
The effect of disease modifying therapies on disease progression in patients with relapsing-remitting multiple sclerosis: a systematic review and meta-analysis
G Tsivgoulis, AH Katsanos, N Grigoriadis… - PLoS …, 2015 - journals.plos.org
Importance A number of officially approved disease-modifying drugs (DMD) are currently
available for the early intervention in patients with relapsing-remitting multiple sclerosis …
available for the early intervention in patients with relapsing-remitting multiple sclerosis …
Comparative efficacy of therapies for relapsing multiple sclerosis: a systematic review and network meta-analysis
IA Samjoo, C Drudge, S Walsh… - Journal of …, 2023 - becarispublishing.com
Aim: To assess the relative efficacy of disease-modifying therapies (DMTs) for relapsing
multiple sclerosis (RMS) including newer therapies (ozanimod, ponesimod, ublituximab) …
multiple sclerosis (RMS) including newer therapies (ozanimod, ponesimod, ublituximab) …